A prospective, longitudinal, observational cohort study examining how glaucoma affects quality of life and visually-related function over 4 years: design and methodology

Michael Waisbourd, Samantha Parker, Feyzahan Ekici, Patricia Martinez, Rachel Murphy, Katie Scully, Sheryl S Wizov, Lisa A Hark, George L Spaeth, Michael Waisbourd, Samantha Parker, Feyzahan Ekici, Patricia Martinez, Rachel Murphy, Katie Scully, Sheryl S Wizov, Lisa A Hark, George L Spaeth

Abstract

Background: The aim of this study is to summarize the design and methodology of a prospective, longitudinal, observational cohort study to investigate how glaucoma affects patients' quality of life and visually-related function over a 4-year period.

Methods/design: One hundred sixty-one (161) subjects were enrolled in this ongoing study. Patients between the ages of 21-85 years with a minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure glaucoma or pseudoexfoliation glaucoma were included. Each patient visited Wills Eye Hospital for a baseline visit. Follow-up is planned for a minimum of 4 years, with annual visits. Each visit includes (1) Clinical evaluation: a slit lamp examination, fundoscopy, intraocular pressure measurement, visual field examination, spectral domain optical coherence tomography, Pelli-Robson Contrast Sensitivity test and the Spaeth-Richman Contrast Sensitivity test; (2) a performance based measure: the Compressed Assessment of Ability Related to Vision; and (3) Subjective measures of vision-related quality of life (the National Eye Institute Visual Functioning Questionnaire 25 and the Modified Glaucoma Symptom Scale).

Discussion: The results of this ongoing, prospective, longitudinal study are expected to shed light on the relationships between clinical measures, performance-based measures and subjective measures of well-being, in order to assess changes in the quality of life and the ability to function of patients with glaucoma over time.

Figures

Fig. 1
Fig. 1
Spaeth Richman Contrast Sensitivity Test (SPARCS). Two parallel horizontal lines and 2 parallel vertical lines intersect to create 9 boxes, including a 5 cm rectangle in the center. Note the darkened square waves in the right upper quadrant. During a “set”, darkened square waves randomly appear briefly in 1 of the 5 tested areas while the other 4 areas remain the same shade as the background. Contrast between the bars and background decreases by 50 % after each cycle

References

    1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267. doi: 10.1136/bjo.2005.081224.
    1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090. doi: 10.1016/j.ophtha.2014.05.013.
    1. Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R, Sherwood M, Meng K, Mangione CM. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol. 1997;115:777–784. doi: 10.1001/archopht.1997.01100150779014.
    1. Hickey A, Barker M, McGee H, O'Boyle C. Measuring health-related quality of life in older patient populations: a review of current approaches. Pharmacoeconomics. 2005;23:971–993. doi: 10.2165/00019053-200523100-00002.
    1. Magacho L, Lima FE, Nery AC, Sagawa A, Magacho B, Avila MP. Quality of life in glaucoma patients: regression analysis and correlation with possible modifiers. Ophthalmic Epidemiol. 2004;11:263–270. doi: 10.1080/09286580490515251.
    1. Spaeth G, Walt J, Keener J. Evaluation of quality of life for patients with glaucoma. Am J Ophthalmol. 2006;141:S3–14. doi: 10.1016/j.ajo.2005.07.075.
    1. Gracitelli CP, Abe RY, Tatham AJ, Rosen PN, Zangwill LM, Boer ER, Weinreb RN, Medeiros FA. Association between progressive retinal nerve fiber layer loss and longitudinal change in quality of life in glaucoma. JAMA Ophthalmol. 2015;133:384–390. doi: 10.1001/jamaophthalmol.2014.5319.
    1. van Gestel A, Webers CA, Beckers HJ, van Dongen MC, Severens JL, Hendrikse F, Schouten JS. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond) 2010;24:1759–1769. doi: 10.1038/eye.2010.133.
    1. McKean-Cowdin R, Wang Y, Wu J, Azen SP, Varma R, Los Angeles Latino Eye Study Group Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115:941–948. doi: 10.1016/j.ophtha.2007.08.037.
    1. Freeman EE, Munoz B, West SK, Jampel HD, Friedman DS. Glaucoma and quality of life: the Salisbury Eye Evaluation. Ophthalmology. 2008;115:233–238. doi: 10.1016/j.ophtha.2007.04.050.
    1. Hyman LG, Komaroff E, Heijl A, Bengtsson B, Leske MC, Early Manifest Glaucoma Trial Group Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005;112:1505–1513. doi: 10.1016/j.ophtha.2005.03.028.
    1. Jampel HD, Schwartz A, Pollack I, Abrams D, Weiss H, Miller R. Glaucoma patients' assessment of their visual function and quality of life. J Glaucoma. 2002;11:154–163. doi: 10.1097/00061198-200204000-00012.
    1. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE, Mills RP, Group CS. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108:1954–1965. doi: 10.1016/S0161-6420(01)00874-0.
    1. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE. Quality of life in newly diagnosed glaucoma patients : The Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2001;108:887–897. doi: 10.1016/S0161-6420(00)00624-2.
    1. Hochberg C, Maul E, Chan ES, Van Landingham S, Ferrucci L, Friedman DS, Ramulu PY. Association of vision loss in glaucoma and age-related macular degeneration with IADL disability. Invest Ophthalmol Vis Sci. 2012;53:3201–3206. doi: 10.1167/iovs.12-9469.
    1. Lorenzana L, Lankaranian D, Dugar J, Mayer J, Palejwala N, Kulkarni K, Warrian K, Boghara Z, Richman J, Wizov S, et al. A new method of assessing ability to perform activities of daily living: design, methods and baseline data. Ophthalmic Epidemiol. 2009;16:107–114. doi: 10.1080/09286580902738142.
    1. Richman J, Lorenzana LL, Lankaranian D, Dugar J, Mayer J, Wizov SS, Spaeth GL. Importance of visual acuity and contrast sensitivity in patients with glaucoma. Arch Ophthalmol. 2010;128:1576–1582. doi: 10.1001/archophthalmol.2010.275.
    1. Richman J, Lorenzana LL, Lankaranian D, Dugar J, Mayer JR, Wizov SS, Spaeth GL. Relationships in glaucoma patients between standard vision tests, quality of life, and ability to perform daily activities. Ophthalmic Epidemiol. 2010;17:144–151. doi: 10.3109/09286581003734878.
    1. Wei H, Sawchyn AK, Myers JS, Katz LJ, Moster MR, Wizov SS, Steele M, Lo D, Spaeth GL. A clinical method to assess the effect of visual loss on the ability to perform activities of daily living. Br J Ophthalmol. 2012;96:735–741. doi: 10.1136/bjophthalmol-2011-300093.
    1. Bayer A, Harasymowycz P, Henderer JD, Steinmann WG, Spaeth GL. Validity of a new disk grading scale for estimating glaucomatous damage: correlation with visual field damage. Am J Ophthalmol. 2002;133:758–763. doi: 10.1016/S0002-9394(02)01422-8.
    1. Danesh-Meyer HV, Ku JY, Papchenko TL, Jayasundera T, Hsiang JC, Gamble GD. Regional correlation of structure and function in glaucoma, using the Disc Damage Likelihood Scale, Heidelberg Retina Tomograph, and visual fields. Ophthalmology. 2006;113:603–611. doi: 10.1016/j.ophtha.2005.10.055.
    1. Henderer JD, Liu C, Kesen M, Altangerel U, Bayer A, Steinmann WC, Spaeth GL. Reliability of the disk damage likelihood scale. Am J Ophthalmol. 2003;135:44–48. doi: 10.1016/S0002-9394(02)01833-0.
    1. Hornova J, Kuntz Navarro JB, Prasad A, Freitas DG, Nunes CM. Correlation of Disc Damage Likelihood Scale, visual field, and Heidelberg Retina Tomograph II in patients with glaucoma. Eur J Ophthalmol. 2008;18:739–747.
    1. Spaeth GL, Henderer J, Liu C, Kesen M, Altangerel U, Bayer A, Katz LJ, Myers J, Rhee D, Steinmann W. The disc damage likelihood scale: reproducibility of a new method of estimating the amount of optic nerve damage caused by glaucoma. Trans Am Ophthalmol Soc. 2002;100:181–185.
    1. Mantyjarvi M, Laitinen T. Normal values for the Pelli-Robson contrast sensitivity test. J Cataract Refract Surg. 2001;27:261–266. doi: 10.1016/S0886-3350(00)00562-9.
    1. Richman J, Zangalli C, Lu L, Wizov SS, Spaeth E, Spaeth GL, 1 The Spaeth/Richman contrast sensitivity test (SPARCS): design, reproducibility and ability to identify patients with glaucoma. Br J Ophthalmol. 2014;99:16–20. doi: 10.1136/bjophthalmol-2014-305223.
    1. Warrian KJ, Lorenzana LL, Lankaranian D, Dugar J, Wizov SS, Spaeth GL. The assessment of disability related to vision performance-based measure in diabetic retinopathy. Am J Ophthalmol. 2010;149:852–860. doi: 10.1016/j.ajo.2009.12.028.
    1. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050–1058. doi: 10.1001/archopht.119.7.1050.
    1. Lee BL, Gutierrez P, Gordon M, Wilson MR, Cioffi GA, Ritch R, Sherwood M, Mangione CM. The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol. 1998;116:861–866. doi: 10.1001/archopht.116.7.861.
    1. Muthen B, Brown CH, Masyn K, Jo B, Khoo ST, Yang CC, Wang CP, Kellam SG, Carlin JB, Liao J. General growth mixture modeling for randomized preventive interventions. Biostatistics (Oxford, England) 2002;3:459–475. doi: 10.1093/biostatistics/3.4.459.
    1. Muthen B, Shedden K. Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics. 1999;55:463–469. doi: 10.1111/j.0006-341X.1999.00463.x.
    1. Elliott MR, Gallo JJ, Ten Have TR, Bogner HR, Katz IR. Using a Bayesian latent growth curve model to identify trajectories of positive affect and negative events following myocardial infarction. Biostatistics (Oxford, England) 2005;6:119–143. doi: 10.1093/biostatistics/kxh022.
    1. Altangerel U, Spaeth GL, Steinmann WC. Assessment of function related to vision (AFREV) Ophthalmic Epidemiol. 2006;13:67–80. doi: 10.1080/09286580500428500.
    1. Friedman DS, Freeman E, Munoz B, Jampel HD, West SK. Glaucoma and mobility performance: the Salisbury Eye Evaluation Project. Ophthalmology. 2007;114:2232–2237. doi: 10.1016/j.ophtha.2007.02.001.
    1. Haymes SA, Johnston AW, Heyes AD. The development of the Melbourne low-vision ADL index: a measure of vision disability. Invest Ophthalmol Vis Sci. 2001;42:1215–1225.
    1. Haymes SA, LeBlanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Glaucoma and on-road driving performance. Invest Ophthalmol Vis Sci. 2008;49:3035–3041. doi: 10.1167/iovs.07-1609.
    1. Ramulu PY, West SK, Munoz B, Jampel HD, Friedman DS. Glaucoma and reading speed: the Salisbury Eye Evaluation project. Arch Ophthalmol. 2009;127:82–87. doi: 10.1001/archophthalmol.2008.523.
    1. Scott IU, Feuer WJ, Jacko JA. Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. Am J Ophthalmol. 2002;133:350–357. doi: 10.1016/S0002-9394(01)01406-4.
    1. Turano KA, Rubin GS, Quigley HA. Mobility performance in glaucoma. Invest Ophthalmol Vis Sci. 1999;40:2803–2809.
    1. Guyatt GH. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol. 1993;22:185A–191A. doi: 10.1016/0735-1097(93)90488-M.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe